Interleukin-7 Enhances the in Vivo Anti-tumor Activity of Tumor-reactive CD8+ T cells with Induction of IFN-gamma in a Murine Breast Cancer Model |
Yuan, Chun-Hui
(Department of Laboratory Medicine and Center for Gene Diagnosis, Zhongnan Hospital of Wuhan University)
Yang, Xue-Qin (Medical School of Jingchu University of Technology) Zhu, Cheng-Liang (Department of Laboratory Medicine, Renmin Hospital of Wuhan University) Liu, Shao-Ping (Hubei Key Laboratory of Tumor Biological Behavior & Hubei Cancer Clinical Study Center) Wang, Bi-Cheng (Department of Laboratory Medicine and Center for Gene Diagnosis, Zhongnan Hospital of Wuhan University) Wang, Fu-Bing (Department of Laboratory Medicine and Center for Gene Diagnosis, Zhongnan Hospital of Wuhan University) |
1 | Verhoeyen E, Dardalhon V, Ducrey-Rundquist O, et al (2003). IL-7 surface-engineered lentiviral vectors promote survival and efficient gene transfer in resting primary T lymphocytes. Blood, 101, 2167-74. DOI |
2 | Vudattu NK, Magalhaes I, Schmidt M, et al (2007). Reduced numbers of IL-7 receptor (CD127) expressing immune cells and IL-7-signaling defects in peripheral blood from patients with breast cancer. Int J Cancer, 121, 1512-9. DOI |
3 | Wu B, Shen RN, Wang WX, et al (1993). Antitumor effect of interleukin 7 in combination with local hyperthermia in mice bearing B16a melanoma cells. Stem Cells, 11, 412-21. DOI |
4 | Yang H, Spencer AU, Teitelbaum DH (2005). Interleukin-7 administration alters intestinal intraepithelial lymphocyte phenotype and function in vivo. Cytokine, 31, 419-28. DOI |
5 | Zaidi MR, Merlino G (2011). The two faces of interferon-gamma in cancer. Clin Cancer Res, 17, 6118-24. DOI |
6 |
Rubinstein MP, Lind NA, Purton JF, et al (2008). IL-7 and IL-15 differentially regulate |
7 | Roato I, Brunetti G, Gorassini E, et al (2006). IL-7 up-regulates TNF-alpha-dependent osteoclastogenesis in patients affected by solid tumor. PLoS One, 1, e124. DOI |
8 |
Rosenberg SA, Sportes C, Ahmadzadeh M, et al (2006). IL-7 administration to humans leads to expansion of |
9 | Sharma S, Batra RK, Yang SC, et al (2003). Interleukin-7 genemodified dendritic cells reduce pulmonary tumor burden in spontaneous murine bronchoalveolar cell carcinoma. Hum Gene Ther, 14, 1511-24. DOI |
10 | Sharma S, Wang J, Huang M, et al (1996). Interleukin-7 gene transfer in non-small-cell lung cancer decreases tumor proliferation, modifies cell surface molecule expression, and enhances antitumor reactivity. Cancer Gene Ther, 3, 302-13. |
11 | Unsinger J, McGlynn M, Kasten KR, et al (2010). IL-7 promotes T cell viability, trafficking, and functionality and improves survival in sepsis. J Immunol, 184, 3768-79. DOI |
12 | Strengell M, Matikainen S, Siren J, et al (2003). IL-21 in synergy with IL-15 or IL-18 enhances IFN-gamma production in human NK and T cells. J Immunol, 170, 5464-9. DOI |
13 | Tanaka H, Yoshizawa H, Yamaguchi Y, et al (1999). Successful adoptive immunotherapy of murine poorly immunogenic tumor with specific effector cells generated from genemodified tumor-primed lymph node cells. J Immunol, 162, 3574-82. |
14 | Terabe M, Park JM, Berzofsky JA (2004). Role of IL-13 in regulation of anti-tumor immunity and tumor growth. Cancer Immunol Immunother, 53, 79-85. DOI ScienceOn |
15 | Liu S, Lizee G, Lou Y, et al (2007). IL-21 synergizes with IL-7 to augment expansion and anti-tumor function of cytotoxic T cells. Int Immunol, 19, 1213-21. DOI |
16 | Lai L, Jin J, Goldschneider I (2011). In vivo antitumor activity of a recombinant IL-7/HGFbeta hybrid cytokine in mice. Cancer Res, 71, 61-7. |
17 | Lee S, Margolin K (2011). Cytokines in cancer immunotherapy. Cancers, 3, 3856-93. DOI ScienceOn |
18 | Li B, VanRoey MJ, Jooss K (2007). Recombinant IL-7 enhances the potency of GM-CSF-secreting tumor cell immunotherapy. Clin Immunol, 123, 155-65. DOI |
19 | Lo CH, Lee SC, Wu PY, et al (2003). Antitumor and antimetastatic activity of IL-23. J Immunol, 171, 600-7. DOI |
20 | Lundstrom W, Fewkes NM, Mackall CL (2012). IL-7 in human health and disease. Semin Immunol, 24, 218-24. DOI |
21 | Pellegrini M, Calzascia T, Toe JG, et al (2011). IL-7 engages multiple mechanisms to overcome chronic viral infection and limit organ pathology. Cell, 144, 601-13. DOI ScienceOn |
22 | Lynch DH, Miller RE (1994). Interleukin-7 promotes long-term in vitro growth of antitumor cytotoxic T lymphocytes with immunotherapeutic efficacy in vivo. J Exp Med, 179, 31-42. DOI |
23 | Murphy WJ, Back TC, Conlon KC, et al (1993). Antitumor effects of interleukin-7 and adoptive immunotherapy on human colon carcinoma xenografts. J Clin Invest, 92, 1918-24. DOI |
24 | Pellegrini M, Calzascia T, Elford AR, et al (2009). Adjuvant IL-7 antagonizes multiple cellular and molecular inhibitory networks to enhance immunotherapies. Nat Med, 15, 528-36. DOI |
25 | Pellegrini M, Mak TW (2010). Tumor immune therapy: lessons from infection and implications for cancer-can IL-7 help overcome immune inhibitory networks? Eur J Immunol, 40, 1852-61. DOI |
26 |
Finke S, Trojaneck B, Lefterova P, et al (1998). Increase of proliferation rate and enhancement of antitumor cytotoxicity of expanded human |
27 | Andersson A, Yang SC, Huang M, et al (2009). IL-7 promotes CXCR3 ligand-dependent T cell antitumor reactivity in lung cancer. J Immunol, 182, 6951-8. DOI |
28 | Appasamy PM (1999). Biological and clinical implications of interleukin-7 and lymphopoiesis. Cytokines Cell Mol Ther, 5, 25-39. |
29 | Ferrari G, King K, Rathbun K, et al (1995). IL-7 enhancement of antigen-driven activation/expansion of HIV-1-specific cytotoxic T lymphocyte precursors (CTLp). Clin Exp Immunol, 101, 239-48. DOI |
30 | Fry TJ, Mackall CL (2002). Interleukin-7: from bench to clinic. Blood, 99, 3892-904. DOI ScienceOn |
31 | Geiselhart LA, Humphries CA, Gregorio TA, et al (2001). IL-7 administration alters the CD4:CD8 ratio, increases T cell numbers, and increases T cell function in the absence of activation. J Immunol, 166, 3019-27. DOI |
32 | Jicha DL, Mule JJ, Rosenberg SA (1991). Interleukin-7 generates antitumor cytotoxic T lymphocytes against murine sarcomas with efficacy in cellular adoptive immunotherapy. J Exp Med, 174, 1511-5. DOI |
33 |
Klebanoff CA, Finkelstein SE, Surman DR, et al (2004). IL-15 enhances the in vivo antitumor activity of tumor-reactive |
34 |
Klebanoff CA, Gattinoni L, Restifo NP (2006). |
35 | Krawczenko A, Kieda C and Duś D (2005). The biological role and potential therapeutic application of interleukin-7. Arch Immunol Ther Exp (Warsz), 53, 518-25. |
36 | Anderson RJ, Schneider J (2007). Plasmid DNA and viral vector-based vaccines for the treatment of cancer. Vaccine, 25, B24-34. DOI |
![]() |